Research programme: receptor tyrosine protein kinase like orphan receptor inhibitorsAlternative Names: ROR1 inhibitors - Oncternal Therapeutics, Inc.
Latest Information Update: 06 Jun 2016
Price : *
At a glance
- Originator University of California, San Diego
- Developer Oncternal Therapeutics, Inc.; University of California, San Diego
- Class Antibodies; CAR-T cell therapies; Drug conjugates; Gene therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunologic cytotoxicity; Receptor protein-tyrosine kinase antagonists; T lymphocyte replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer